Current Biotechnological Approaches to the Prevention of Restenosis

In this: publication
By this: publisher
In this Subject: Pharmacology
By this author: Nikol S. ;&nbsp; Maier A. ;&nbsp; Krausz E. ;&nbsp; H&ouml;fling B. ;&nbsp; Huehns T.Y.

Authors: Nikol S.; Maier A.; Krausz E.; Höfling B.; Huehns T.Y.

Source: BioDrugs, Volume 9, Number 5, 1 May 1998 , pp. 375-388(14)

Buy & download fulltext article:

Price: $62.95 plus tax (Refund Policy)

Abstract:

No systemic pharmacological treatment has been convincingly shown to reduce the incidence of restenosis after angioplasty in patients. The lack of success of many pharmaceutical agents in reducing restenosis rates post-angioplasty and following stent implantation, as documented in dozens of clinical trials, has encouraged the development of new biotechnological approaches to the treatment of restenosis. Gene therapy and other agents, including antibodies, fusion toxins and ribozymes, have the potential to prevent some of the sequelae after arterial injury, particularly cell proliferation. Mechanical methods of preventing restenosis, for example sophisticated local drug delivery strategies and biodegradable stents using new materials, in combination with novel therapeutic agents or radiation, may also be of use.

Keywords: Restenosis, prevention; Growth-factors, therapeutic-use; Osteopontin, therapeutic-use; Research-and-development; Abciximab, therapeutic-use; Biotechnology; Ribozymes, therapeutic-use; Plicamycin, therapeutic-use; Drug-delivery-systems; Angioplasty; Nucleotides, therapeutic-use; Antithrombotics, therapeutic-use; Gene-therapies, therapeutic-use; Enzymes, therapeutic-use; Antihyperlipidaemics, therapeutic-use; Phototherapy; Coronary-disorders; Coronary-stenting